Jian Dong

Synergistic antitumor effect of the anti-ErbB2 antibodies trastuzumab and H2-18 on trastuzumab-resistant gastric cancer cells

Bo-hua Li, Bei-bei Liang, Y. Meng, 2021, Oncology letters.

Combined SRC inhibitor saracatinib and anti-ErbB2 antibody H2-18 produces a synergistic antitumor effect on trastuzumab-resistant breast cancer.

Jian Zhao, Huajing Wang, Hao Wang, 2016, Biochemical and biophysical research communications.

Inhibition of nemo-like kinase increases taxol sensitivity in laryngeal cancer.

Yan Li, Nan Guo, Pin-Duo Liu, 2013, Asian Pacific journal of cancer prevention : APJCP.

The anti-ErbB2 antibody H2-18 and the pan-PI3K inhibitor GDC-0941 effectively inhibit trastuzumab-resistant ErbB2-overexpressing breast cancer.

Jian Zhao, Chaohua Hu, Huajing Wang, 2017, Oncotarget.

A monoclonal antibody targeting ErbB2 domain III inhibits ErbB2 signaling and suppresses the growth of ErbB2-overexpressing breast tumors

Huajing Wang, Lin-hui Wang, Xiaojie Yu, 2016, Oncogenesis.

A bispecific anti-ErbB2 antibody potently induces ErbB2 internalization and suppresses ErbB2-overexpressing tumor growth.

Jian Zhao, Huajing Wang, Bo-hua Li, 2016, Biochemical and biophysical research communications.